A recent prospective cohort study by Liu et al. [129], which followed 1902 individuals with type 2 diabetes over a median period of 7.2 years, demonstrated that elevated baseline plasma PCSK9 levels were independently linked to a higher risk of CKD progression, defined as either a doubling of serum creatinine or the onset of end-stage kidney disease. This evidence concerns the gene PCSK9 and type 2 diabetes mellitus.